Literature DB >> 23635408

A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia.

Carl Eckerström1, Erik Olsson, Maria Bjerke, Helge Malmgren, Ake Edman, Anders Wallin, Arto Nordlund.   

Abstract

BACKGROUND: Mild cognitive impairment (MCI) is a condition with increased risk for further cognitive decline. A considerable challenge lies in predicting which patients will eventually convert to dementia.
OBJECTIVE: To study prediction of dementia in MCI using neuropsychological tests, commonly used cerebrospinal fluid (CSF) biomarkers, and hippocampal volume.
METHODS: Twenty-one MCI patients converting to dementia, 21 stable MCI patients, and 26 controls were included in the study with a follow-up time of two years. The study participants underwent comprehensive examinations at inclusion: a neuropsychological assessment comprising 20 tests, MRI scanning with subsequent hippocampal volumetry, and CSF analyses of T-tau, P-tau, and Aβ42.
RESULTS: Neuropsychological tests, hippocampal volume, and the CSF markers Aβ42, P-tau, and T-tau all predicted conversion from MCI to dementia. A combination of all classes of markers was the most successful at predicting dementia (AUC 0.96) with a memory test (RAVLT) as the best individual predictor (AUC 0.93). Similar findings are reported for the prediction of Alzheimer's disease.
CONCLUSION: Neuropsychological tests were the best individual predictors of dementia. A combination of markers improved the predictive ability with the combination of neuropsychological tests, CSF, and hippocampal volume as the best predictors of dementia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23635408     DOI: 10.3233/JAD-122440

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  24 in total

Review 1.  The Gothenburg MCI study: Design and distribution of Alzheimer's disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up.

Authors:  Anders Wallin; Arto Nordlund; Michael Jonsson; Karin Lind; Åke Edman; Mattias Göthlin; Jacob Stålhammar; Marie Eckerström; Silke Kern; Anne Börjesson-Hanson; Mårten Carlsson; Erik Olsson; Henrik Zetterberg; Kaj Blennow; Johan Svensson; Annika Öhrfelt; Maria Bjerke; Sindre Rolstad; Carl Eckerström
Journal:  J Cereb Blood Flow Metab       Date:  2016-01       Impact factor: 6.200

2.  Diagnostic Accuracy of Memory Measures in Alzheimer's Dementia and Mild Cognitive Impairment: a Systematic Review and Meta-Analysis.

Authors:  Gali H Weissberger; Jessica V Strong; Kayla B Stefanidis; Mathew J Summers; Mark W Bondi; Nikki H Stricker
Journal:  Neuropsychol Rev       Date:  2017-09-22       Impact factor: 7.444

3.  Extension and refinement of the predictive value of different classes of markers in ADNI: four-year follow-up data.

Authors:  Jesus J Gomar; Concepcion Conejero-Goldberg; Peter Davies; Terry E Goldberg
Journal:  Alzheimers Dement       Date:  2014-03-06       Impact factor: 21.566

4.  Predicting Alzheimer's Disease Using Combined Imaging-Whole Genome SNP Data.

Authors:  Dehan Kong; Kelly S Giovanello; Yalin Wang; Weili Lin; Eunjee Lee; Yong Fan; P Murali Doraiswamy; Hongtu Zhu
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

5.  Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment.

Authors:  Benjamin M Kandel; Brian B Avants; James C Gee; Steven E Arnold; David A Wolk
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

6.  Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment.

Authors:  Pia Kivisäkk; Colin Magdamo; Bianca A Trombetta; Ayush Noori; Yi Kai E Kuo; Lori B Chibnik; Becky C Carlyle; Alberto Serrano-Pozo; Clemens R Scherzer; Bradley T Hyman; Sudeshna Das; Steven E Arnold
Journal:  Brain Commun       Date:  2022-06-14

7.  Harnessing forgetfulness: can episodic-memory tests predict early Alzheimer's disease?

Authors:  Samuel L Warren; Ahmed A Moustafa; Hany Alashwal
Journal:  Exp Brain Res       Date:  2021-07-27       Impact factor: 1.972

Review 8.  Identification of potential or preclinical cognitive impairment and the implications of sophisticated screening with biomarkers and cognitive testing: does it really matter?

Authors:  Michael Gordon
Journal:  Biomed Res Int       Date:  2013-07-08       Impact factor: 3.411

Review 9.  Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.

Authors:  Qingwei Ruan; Grazia D'Onofrio; Daniele Sancarlo; Zhijun Bao; Antonio Greco; Zhuowei Yu
Journal:  BMC Geriatr       Date:  2016-05-16       Impact factor: 3.921

Review 10.  Alzheimer's disease--subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies.

Authors:  Anders Wallin; Arto Nordlund; Michael Jonsson; Kaj Blennow; Henrik Zetterberg; Annika Öhrfelt; Jacob Stålhammar; Marie Eckerström; Mårten Carlsson; Erik Olsson; Mattias Göthlin; Johan Svensson; Sindre Rolstad; Carl Eckerström; Maria Bjerke
Journal:  J Cereb Blood Flow Metab       Date:  2016-01       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.